Legend Biotech (LEGN) to Release Earnings on Monday

Key Points

• Legend Biotech is set to release its Q2 2025 earnings on August 11th, with analysts anticipating a loss of ($0.18) per share and revenues of $237.49 million.
• In the previous quarter, the company reported a narrower loss of ($0.07) EPS and revenues of $195.05 million, representing a year-over-year revenue increase of 107.8%.
• Analysts maintain a positive outlook on Legend Biotech, with an average price target of $73.33 and ten analysts giving a buy rating on the stock.

Legend Biotech (NASDAQ:LEGN - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Legend Biotech to post earnings of ($0.18) per share and revenue of $237.49 million for the quarter.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.33. Legend Biotech had a negative net margin of 29.95% and a negative return on equity of 21.19%. The firm had revenue of $195.05 million during the quarter, compared to analysts' expectations of $190.83 million. During the same period in the previous year, the company earned ($0.16) EPS. The firm's revenue for the quarter was up 107.8% compared to the same quarter last year. On average, analysts expect Legend Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Legend Biotech Price Performance

LEGN stock opened at $38.76 on Monday. Legend Biotech has a 12 month low of $27.34 and a 12 month high of $59.62. The company has a current ratio of 5.20, a quick ratio of 5.07 and a debt-to-equity ratio of 0.30. The company has a 50-day moving average price of $36.34 and a 200 day moving average price of $35.05. The stock has a market cap of $7.12 billion, a PE ratio of -65.63 and a beta of 0.26.

Wall Street Analysts Forecast Growth

Several research firms recently commented on LEGN. Royal Bank Of Canada reiterated an "outperform" rating and set a $84.00 price objective on shares of Legend Biotech in a research note on Tuesday, April 22nd. UBS Group set a $54.00 price objective on shares of Legend Biotech and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Morgan Stanley reiterated an "overweight" rating and set a $81.00 price objective (up previously from $80.00) on shares of Legend Biotech in a research note on Thursday, July 10th. Cantor Fitzgerald reiterated an "overweight" rating and set a $55.00 price objective on shares of Legend Biotech in a research note on Wednesday, May 14th. Finally, HC Wainwright reiterated a "buy" rating and set a $75.00 price objective on shares of Legend Biotech in a research note on Thursday, July 17th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $73.33.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.